Stock Financial Ratios, Dividends, Split History

CIT / CIT Group, Inc. (The) financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price52.16
Volume1,147,300.00
Market Cap ($M)6,601.07
Enterprise Value ($M)17,035.83
Book Value ($M)7,126.80
Book Value / Share56.09
Price / Book0.93
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 163,950,000
Common Stock Shares Outstanding 131,352,924
Common Shares Outstanding 130,769,978
Weighted Average Number Of Shares Outstanding Basic 162,290,000
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.03
Return on Assets (ROA)0.01
Return on Equity (ROE)0.05
Balance Sheet (mrq) ($M)
Assets51,542.50
Liabilities44,415.70
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Revenues3,207,200,000.00
Other Revenues0.00
Accrued Fees And Other Revenue Receivable472,100,000.00
Net Income468.20
Earnings Per Share Basic2.82
Earnings Per Share Diluted2.80
Cash Flow Statement (mra) ($M)
Cash From Operations519.80
Cash from Investing7,755.20
Cash from Financing7,755.20
Identifiers and Descriptors
CUSIP125581801
Central Index Key (CIK)1171825
Related CUSIPS
125581951 012558180 047294037 125581901
Industry Groups

Split History

Stock splits are used by CIT Group, Inc. (The) to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Stocks To Watch: A New Beverage Giant Steps Out

2018-07-07 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (232-3)

Oppenheimer Says Financials Are Cheap: 4 to Buy Now

2018-07-05 247wallst
By any measure, the financial sector is one of the cheapest of all in the S&P 500, and despite some very positive tailwinds, the sector has lagged dramatically this year. The good news for investors looking to add or increase positions in the sector is that with the stress tests out of the way and mostly positive, and the direction of interest rates pointing higher, now may be the best time to buy some of the top companies. (57-0)

Top Analyst Upgrades and Downgrades: Accenture, Ally, Diageo, Harley-Davidson, KB Home, NetApp, Nike, Sirius XM, Walgreens and More

2018-06-29 247wallst
Stocks were looking for a stronger open on Friday for the last trading day of the second quarter of 2018. That said, the year-to-date performance has been down 2% for the Dow Jones industrial average and a 1.5% gain for the S&P 500. The trend of buying the dips has not worked as well as it has in prior years, and many investors have been considering how they want their investments positioned for the longer term. (121-0)

U.S. business borrowing for equipment flat in May - ELFA

2018-06-25 reuters
(Reuters) - U.S. companies’ borrowing to spend on capital investment was little changed in May from a year earlier, the Equipment Leasing and Finance Association (ELFA) said. (83-0)

3 Bank Stocks to Buy After the Fed’s Stress Tests | InvestorPlace

2018-06-22 investorplace
It’s a controversial process that all financial institutions anxiously await every year. Since the disaster of the 2008 crisis, the U.S. Federal Reserve imposes a stress test on major banks to ensure their viability under recessionary pressures. Fortunately for all concerned, the assessed institutions passed, providing positive sentiment toward bank stocks. (145-0)

CUSIP: 125581801